Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months

Inclusion Criteria: For primary vaccination * Subjects aged 3-5 months; * Subjects should be full-term (37-42 weeks of gestation) and their birth weight should meet the requirements (2500g ≤ body weight ≤ 4000g); * Axillary body temperature ≤ 37.0 ℃; * The guardian signs the informed consent form; * The guardian and his family agree to comply with the requirements of the clinical trial protocol; * Subjects who have not been vaccinated with meningococcal group A and C conjugate vaccine at the aged of 3-5 months; * Subjects who had no history of other live vaccines within 14 days before vaccination and no history of other inactivated vaccines within 7 days; For booster vaccination * Infants in the experimental group who have completed primary immunization in this clinical trial and reach the age of 18 months; * The guardian and his family agree to comply with the requirements of the clinical trial protocol. Exclusion Criteria: For primary vaccination * Test-tube baby who is suffering from perianal abscess, severe eczema or pathological jaundice; * History of severe allergic reactions requiring medical intervention (such as swelling of mouth and throat, dyspnea, hypotension or shock); * A clearly diagnosed history of thrombocytopenia or other coagulation disorders that may cause contraindications to intramuscular injection; * History of Abnormal production process, asphyxia rescue, or congenital malformation, serious developmental disorder, serious genetic defect, serious…